Implications for the EU/EEA of the spread of the SARS-CoV-2 Omicron XBB.1.5 sub-lineage, ECDC
Summary The XBB.1.5 Omicron sub-lineage was first detected in samples in the United States (US) in October 2022. This sub-lineage has been growing in proportion in the US and many countries around the world since then, including in several EU/EEA countries and the UK. XBB.1.5 is a sub-lineage of XBB, which is a recombinant of two earlier lineages of the Omicron variant of concern (VOC), with an additional spike receptor-binding domain (RBD) change S486P. The reported proportion of XBB.1.5 in the EU/EEA has been lower than 2.5% for the last two weeks of 2022. XBB.1.5 currently exhibits a daily growth advantage of 12% in t...
Source: Current Awareness Service for Health (CASH) - January 20, 2023 Category: Consumer Health News Source Type: news

Updated living WHO guideline on drugs for Covid-19, WHO ( updated 13th January 2023)
Update contains new data supporting existing recommendations. Nirmatrelvir/ritonavir is considered also an option for pregnant and breastfeeding women with non-severe illness. Further evidence supports strong recommendations against use of sotrovimab and casirivimab-imdevimab. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 16, 2023 Category: Consumer Health News Source Type: news

VV116 Noninferior to Nirmatrelvir-Ritonavir for COVID-19
FRIDAY, Jan. 6, 2023 -- VV116 is noninferior to nirmatrelvir-ritonavir with respect to time to sustained clinical recovery for adults with mild-to-moderate COVID-19 at risk for progression, according to a study published online Dec. 28 in the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 6, 2023 Category: Pharmaceuticals Source Type: news

Oral Antiviral Matches Paxlovid in High-Risk COVID
(MedPage Today) -- An oral remdesivir analogue (VV116) was just as good as nirmatrelvir-ritonavir (Paxlovid) for the treatment of mild-to-moderate COVID-19 in adults at risk for severe disease, and may be safer, results of a phase III trial from... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - January 3, 2023 Category: Infectious Diseases Source Type: news

Hetero gets WHO prequalification for generic Covid antiviral Paxlovid
This is the first WHO prequalification for Paxlovid - a combination of nirmatrelvir and ritonavir which is recommended for treating mild and moderate Covid patients at the highest risk of hospital admissions, such as unvaccinated, aged, or immunosuppressed patients. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 26, 2022 Category: Pharmaceuticals Source Type: news

Nirmatrelvir Plus Ritonavir Reduces Risks for COVID-19 in Seniors
MONDAY, Dec. 12, 2022 -- Nirmatrelvir plus ritonavir reduces the risk for hospitalization or death after an outpatient diagnosis of COVID-19 among older adults, according to a study published online Dec. 13 in the Annals of Internal Medicine. Scott... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 12, 2022 Category: Pharmaceuticals Source Type: news

Viral Rebound Uncommon After Molnupiravir, Nirmatrelvir-Ritonavir Therapy
FRIDAY, Dec. 9, 2022 -- Patients with COVID-19 taking molnupiravir or nirmatrelvir-ritonavir rarely have viral rebound, and rebound is not associated with increased mortality risk, according to a study published online Dec. 6 in JAMA Network... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 9, 2022 Category: Pharmaceuticals Source Type: news

Paxlovid Safe for Pregnant Patients With COVID-19
FRIDAY, Dec. 9, 2022 -- Pregnant patients treated with nirmatrelvir and ritonavir (Paxlovid) for COVID-19 tolerate the treatment well, according to a study published online Nov. 29 in JAMA Network Open. William M. Garneau, M.D., from the Johns... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 9, 2022 Category: Pharmaceuticals Source Type: news

When Paxlovid Is “Commercialized” In 2023, Patient Access To The Covid-19 Treatment Will Depend On Insurance Status
The oral tablet Paxlovid (nirmatrelvir/ritonavir) is used to treat Covid-19. The antiviral can prevent Covid-19 infections from becoming severe. As such, it has helped many people infected with Covid-19 from being hospitalized or dying. Until now, the federal government has paid for all doses of…#medicare #medicaid #ashishjha #foodanddrugadministration #responseteam (Source: Reuters: Health)
Source: Reuters: Health - December 8, 2022 Category: Consumer Health News Source Type: news

Oral Antivirals for High-Risk COVID-19 Patients Oral Antivirals for High-Risk COVID-19 Patients
Review and compare the safety, efficacy, and clinical data for molnupiravir and ritonavir-boosted nirmatrelvir, two antivirals approved for the treatment of COVID-19 in high risk patients.U.S. Pharmacist (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 5, 2022 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Treatment of Hospital-Onset COVID-19 in Adults and Children, DHSC (updated 28th November 2022)
The published policy has been updated to reflect updated WHO guideline, latest evidence& extension of remdesevir marketing authorisation. Treatments choices are now nirmatrelvir/ritonavir (Paxlovid) (1st line) or remdesivir (2nd line). Exceptionally, sotrovimab may be considered (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 30, 2022 Category: Consumer Health News Source Type: news

Cardiovascular Drug Interactions With NMVr in COVID-19 Patients Cardiovascular Drug Interactions With NMVr in COVID-19 Patients
Nirmatrelvir-ritonavir (NMVr) may have significant interactions with cardiovascular drugs. This paper reviews common ones and the importance of medication reconciliation before initiation of NMVr.Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 14, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Alive Woman Declared Dead; Man's COVID Cured After 400 Days; Doc Dies in Plane Crash
(MedPage Today) -- Note that some links may require subscriptions. Two Denver firefighters were suspended after allegedly getting a physician to declare a living woman dead. (Denver Post) U.S. veterans who took nirmatrelvir-ritonavir (Paxlovid... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 7, 2022 Category: American Health Source Type: news

Non-Paxlovid Rebound; Pandemic Spike in Early Puberty; New Therapy for Nightmares?
(MedPage Today) -- Note that some links may require subscriptions. Outpatient COVID treatment with nirmatrelvir-ritonavir (Paxlovid) was 36% and 30% lower for Black and Hispanic patients compared with white patients, a CDC report found. A high... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - October 28, 2022 Category: Psychiatry Source Type: news

What Happens If I Get COVID-19 and the Flu at the Same Time?
So far, COVID-19 has come with one small silver lining for health: cases of influenza have dropped dramatically. During the first flu season during the pandemic, lockdowns kept people indoors and away from one another, limiting the virus’ ability to spread. And once people began mingling more during the next flu seasons, widespread use of masks blocked influenza’s chances of infecting large numbers of people. But that could change this flu season, as mask mandates have disappeared and more people are interacting in close quarters in school, workplaces, sports events, public transport, and more. Health experts a...
Source: TIME: Health - October 11, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news